Table 1.
Clinical characteristics of the GIST patients at tissue collection.
| Characteristics | No. (%) |
|---|---|
| Age (year) | |
| median (range) | 59 (28–88) |
| ≤59 | 93 (50.3) |
| >59 | 92 (49.7) |
| Sex | |
| male | 97 (52.4) |
| female | 88 (47.6) |
| Primary site | |
| stomach | 87 (47.0) |
| small bowel | 88 (47.6) |
| large intestine | 8 (4.3) |
| others | 2 (1.1) |
| Disease status | |
| before TKI | 66 (35.7) |
| after TKI | 119 (64.3) |
| Largest tumor size (mm) | |
| ≤ 50 | 93 (50.3) |
| 50–100 | 60 (32.4) |
| >100 | 32 (17.3) |
| aPrimary mutation | |
| KIT exon 9 | 26 (14.1) |
| KIT exon 11 | 116 (62.7) |
| Others | 12 (6.5) |
| Wild type | 20 (10.8) |
| NE | 11 (5.9) |
| Resection site for PDX | |
| primary | 87 (47.0) |
| metastasis | 98 (53.0) |
| Drug exposure | |
| No | 66 (35.7) |
| Imatinib alone | 84 (45.4) |
| Imatinib and Sunitinib | 25 (13.5) |
| Imatinib, Sunitinib, and Regorafenib | 10 (5.4) |
| Duration of TKI (months) | |
| Imatinib, median (range) | 34.4 (0.9–145.9) |
| Sunitinib, median (range) | 11.9 (0.7–58.1) |
| Regorafenib, median (range) | 11.1 (3.7–32.9) |
TKI: tyrosine kinase inhibitor.
Wild type: non-KIT and non-PDGFR mutant.
PDX: patient-derived xenograft.
NE: not evaluated.
aMutation analysis in KIT exons 9, 11, 13, 14, and 17, and PDGFRa exons 12 and 18 by Sanger sequencing.